Chugai Pharmaceutical (OTCMKTS:CHGCY) Downgraded to Hold Rating by UBS Group

Posted by Latisha Jones on Aug 8th, 2026

UBS Group lowered shares of Chugai Pharmaceutical (OTCMKTS:CHGCY – Free Report) from a strong-buy rating to a hold rating in a research note published on Thursday morning,Zacks.com reports.

Several other analysts also recently commented on CHGCY. The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Check Out Our Latest Stock Report on CHGCY

Chugai Pharmaceutical Stock Up 2.9%

Chugai Pharmaceutical stock opened at $21.66 on Thursday. Chugai Pharmaceutical has a 12 month low of $20.00 and a 12 month high of $34.84. The company’s fifty day simple moving average is $22.70 and its 200-day simple moving average is $26.02. The stock has a market cap of $71.29 billion, a P/E ratio of 23.54 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last issued its earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. The company had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.71% and a net margin of 35.09%. On average, equities research analysts expect that Chugai Pharmaceutical will post 0.96 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.